Floatz logo

m3814

Stage IVB Prostate Cancer AJCC v8

National Cancer Institute (NCI)Phase 1/2Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
89/ 100

Competitive context

13 Active assets in the Stage IVB Prostate Cancer AJCC v8 cohort.

Asset / SponsorPhaseRating
Fluciclovine
NRG Oncology
Phase 4BB
VIPIVOTIDE TETRAXETAN
Mayo Clinic
Phase 3BB
Hyaluronidase zzxf
Mayo Clinic
Phase 2B
Avelumab
National Cancer Institute (NCI)
Phase 2CCC
Tuvusertib
National Cancer Institute (NCI)
Phase 2CCC

View all 14 →

Same molecule, other indications

m3814 is also rated in:

Advanced Solid TumorsDormant
CCC
Indicative ·
52 / 100
View asset →
Unresectable Malignant Solid NeoplasmDormant
CCC
Indicative ·
50 / 100
View asset →
Locally Advanced Unresectable Gallbladder CarcinomaDormant
CCC
Indicative ·
48 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →